Assessment of safety and clinical tolerability of hdmASIT+TM administered subcutaneously in house dust mite-induced allergic rhinoconjunctivitis patients.
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2017
At a glance
- Drugs House dust mite allergy immunotherapy (Primary)
- Indications Seasonal allergic rhinitis
- Focus Adverse reactions
- Sponsors ASIT biotech
- 10 Aug 2017 Last checked against European Clinical Trials Database record.
- 22 Mar 2017 Status changed from active, no longer recruiting to completed.
- 24 Jan 2017 Results published in an ASIT biotech media release.